Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal.

Lobeglitazone (LGZ), a newly researched thiazolidinedione (TZD) thought to have lesser side effects compared with pioglitazone (PGZ), has been recently approved for the treatment of type 2 diabetes (T2D) in India. We aim to conduct an updated systematic review of LGZ to critically appraise its efficacy and safety in the context of PGZ. A systematic literature search was carried out in the electronic database of PubMed until Jan 15, 2023, using specific keywords and MeSH terms. All studies which evaluated LGZ in people with T2D were retrieved and data were synthesized with regard to its efficacy and safety. A comparative critical appraisal was additionally made in the context of PGZ in T2D. Four randomized controlled, one prospective observational, and two real-world studies have evaluated the safety and efficacy of LGZ against placebo or active comparators either as monotherapy or in combination therapy. HbA1c reduction with LGZ 0.5 mg was superior to the placebo but similar to PGZ 15 mg and sitagliptin (SITA) 100 mg. Weight gain with LGZ was significantly higher compared to placebo and SITA but similar to PGZ. Edema was more frequently observed with LGZ compared to placebo, PGZ, and SITA. No substantial evidence is yet available that suggests LGZ could be a better alternative to PGZ both in the context of glycemic or extra-glycemic effects. At least in the short-term, adverse events of LGZ are indifferent from PGZ. More data is additionally needed to claim any advantage of LGZ over PGZ. • Lobeglitazone (LGZ) is a new thiazolidinedione, recently approved for treating type 2 diabetes (T2D) in India. • HbA1c reduction with LGZ 0.5 mg is superior to placebo but similar to pioglitazone (PGZ) 15 mg and sitagliptin. • Weight gains similar to PGZ but higher than sitagliptin. Edema is more frequent with LGZ compared to both. • No conclusive evidence yet to suggest LGZ can rival PGZ for treating T2D. [ABSTRACT FROM AUTHOR]